Lara Brambilla

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells

Davide Genini, Lara Brambilla, Erik Laurini et al. · Proceedings of the National Academy of Sciences · 2017 · 100 citations · Full text

Medicine, Cancer Biology, Oncology +17

Hitting the right spot: Mechanism of action of OPB‐31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)

Lara Brambilla, Davide Genini, Erik Laurini et al. · Molecular Oncology · 2015 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer

Anastasia Malek, Luz-Elena Núñez, Marco Magistri et al. · PLoS ONE · 2012 · 59 citations · Full text

Medicine, Oncology, Pharmacology +9

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

Madhuri Kalathur, Alberto Toso, Jingjing Chen et al. · Nature Communications · 2015 · 42 citations · Full text

Medicine, Molecular Biology, Oncology +13

Tonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiome

Isabelle Marié, Lara Brambilla, Doua F. Azzouz et al. · eLife · 2021 · 38 citations · Full text

Life Sciences, Immunology, Microbiology +17